Irrespective of their response to esmolol infusion, all patients had a follow-up tilt test with oral metoprolol after an interval of ~5 half-lives of the drug. All 16 patients (100%) with a negative tilt test response during esmolol infusion had a negative tilt test response with oral metoprolol. Of the 11 patients with a positive tilt test response during esmolol infusion, 10 (90%) continued to have a positive response with oral metoprolol.
It is concluded that in the electrophysiology laboratory, esmolol can accurately predict the outcome of a head-up tilt response to oral metoprolol. This information may be helpful in formulating a therapeutic strategy at the initial head-up tilt test in patients with neurocardiogenic syncope. (JAm Coli Cardio/1992; 19:402-8) Methods Study patients. Twenty-seven consecutive patients (18 female and 9 male, 12 to 75 years of age) were included in this study. All patients were referred for evaluation of unexplained syncope and had a positive head-up tilt test response at baseline study (17 patients) or after intravenous administration of isoproterenol (10 patients). Twenty-six patients had two or more episodes and one patient had one episode of syncope in the preceding year. In addition, 20 patients had a history of recurrent presyncope. Comprehensive physical examination, neurologic evaluation, surface electrocardiogram (ECG) and electrophysiologic evaluation did not identify the cause of syncope in any of these patients. Two patients had coronary artery disease. The mean ejection fraction was 63.2% (range 45% to 73%).
Head-up tilt test. During the head-up tilt test, arterial blood pressure was monitored by means of an intraarterial cannula inserted percutaneously into the brachial or femoral artery. Each patient was tilted to 70° for a maximum of 15 min. If the baseline tilt test response was negative, the patient was returned to the supine position and intravenous isoproterenol infusion was started at 1 JLg/min. The infusion rate was gradually increased until a 20% increase in heart rate was achieved and the head-up tilt test was repeated. NSHD  NSHD  NSHD  NSHD  NSHD  NSHD  NSHD  NSHD  NSHD  NSHD  NSHD  NSHD  NSHD  NSHD  NSHD  NSHD  NSHD  NSHD  NSHD  NSHD  NSHD  NSHD  CAD  NSHD  NSHD  CAD  NSHD HUT (10) HUT (15) HUT (6) HUT (7) HUT (14) HUT(S) HUT and Iso (8) HUT and Iso (14) HUT and Iso (6.5) HUT and Iso (6) HUT and lso (5.5) HUT and lso (9) HUT and lso (3) HUT and lso (6.5) HUT and lso (3.5) HUT and Iso (8) HUT (6) HUT(6.5) HUT (6) HUT (3) HUT (2) HUT (10) HUT (7) HUT (10) HUT (5) HUT (7) HUT ( A response was considered positive if significant arterial hypotension in association with syncope or presyncope was encountered. All patients with a positive tilt test response then received an infusion of esmolol at 500 p.g/kg for 3 min followed by a maintenance dose of 300 JLg/kg per min. Five minutes after the start of the infusion, patients were rechal- 
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was repeated under similar circumstances as before (that is, at baseline study or after intravenous isoproterenol). Statistical analysis. The data are expressed as mean values ± SD. Paired and unpaired t test analysis was used to compare heart rate and blood pressure within the same group and between different groups. A p value < 0.05 was considered significant.
Results
Patient characteristics. Table 1 shows the clinical and electrophysiologic characteristics of the 27 patients included in this study. Two patients had documented sinus pauses (3 .5 to 6 s duration), one had complete heart block and two had significant sinus bradycardia and syncope while being monitored in the hospital for earlier episodes of syncope that had occurred outside the hospital.
Seventeen patients had a positive baseline head-up tilt test response and 10 required intravenous isoproterenol (I to 3 pg/min, mean 1. 7) for provocation of hypotension and syncope or presyncope. The mean time to a positive head-up tilt test response at baseline was 7.4 ± 3.4 min (range 2 to . Heart rate changes in the 16 patients who had a negative head-up tilt response during esmolol infusion. A significant decrease in heart rate was seen at baseline tilt, with one patient having asystole. In comparison, a minimal increase or no significant change was seen when the same patients were rechallenged with a head-up tilt test during esmolol infusion and subsequently with oral metoprolol. Format and abbreviations as in Figure 1 . 15 ). The mean time to a positive head-up tilt test with isoproterenol provocation was 6.8 ± 3.2 min (range 2 to 15). Patients with a negative head-up tilt test response during esmolol infusion. Changes in mean arterial pressure and heart rate during the head-up tilt test at baseline, during esmolol infusion and during oral metoprolol therapy are depicted in Figures 1 and 2 . A decrease in mean arterial pressure of 43 ± 13 mm Hg at baseline from the initial upright position to termination of the tilt test was significantly greater than the change recorded during esmolol infusion (-5 ± 5 mm Hg; p < 0.00001 vs. baseline tilt) or with oral metoprolol (I ± 7 mm Hg; p < 0.00001 vs. baseline tilt) ( Fig. 3 ). Furthermore, none of these patients had syncope or presyncope when rechallenged with head-up tilt during esmolol infusion or oral metoprolol. Similarly, heart rate during baseline tilt decreased in all patients except two, with Patient 5 having asystole ( Fig. 4) . A decrease in heart rate of 23 ± 21 beats/min at baseline tilt was significant in comparison with the change during esmolol infusion (8 ± 13 beats/min; p < 0.0004 vs. baseline tilt) and during oral metoprolol therapy (4 ± 14 beats/min; p < 0.0008 vs. baseline tilt) ( Fig. 3 ). Mean arterial pressure and heart rate changes from the initial upright position to termination of the tilt test at baseline, during esmolol infusion and with oral metoprolol are shown in Figures 5 and 6 . The magnitude of the decrease in mean arterial pressure at baseline tilt (-54 ± 22 mm Hg) was similar to that seen during esmolol infusion ( -40 ± 12 mm Hg) and with oral metoprolol (-48 ± 20 mm Hg). Similarly, differences in the decrease in heart at baseline tilt (-27 ± 36 beats/min), during esmolol infusion ( -13 ± 25 beats/min) and with oral metoprolol ( -18· ± 26 beats/min) were insignificant (Fig. 7) . 
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There were no significant differences in age (44 ± 18 vs. 46 ± 17 years) or ejection fraction (62 ± 14% vs. 64 ± 13%) between the groups with a negative or positive head-up tilt test response during esmolol infusion.
Baseline heart rate (72 ± 14 vs. 74 ± 10 beats/min) was similar between the groups with a negative and or positive head-up tilt test response during esmolol infusion. Similarly, mean maximal changes in heart rate from the supine to the initial upright position (21 ± 14 vs. 19 ± 19 beats/min) and from the supine to the upright position during 70° upright tilt positioning (32 ± 19 vs. 28 ± 26 beats/min) did not differ between the two groups. Mean maximal changes in heart rate during esmolol infusion from the supine to the upright position also did not differ between the two groups (11 ± 13 vs. 12 ± 10 beats/min).
Discussion
The head-up tilt test. This study highlights the usefulness of esmolol in combination with the head-up tilt test in predicting patient response to long-term oral beta-blocker Figure 6 . Heart rate changes in the 11 patients who continued to have a positive head-up tilt test response during esmo1ol infusion. Changes in heart rate at baseline tilt, during esmolol infusion and with oral metoprolol were significant. Two patients had asystole at baseline tilt and with oral metoprolol. One of these patients also had asystole on esmolol. The broken line is as defined in Figure 5 . Format and abbreviations as in Figure I .
therapy. Head-up tilt testing is increasingly being used as a diagnostic tool in patients with unexplained syncope; previous reports (4) have shown its high reproducibility rate in such patients. In most patients, the phenomenon of neurocardiogenic syncope is characterized by prodromal symptoms of pallor, yawning, nausea and sweating; in others, loss of consciousness may be abrupt. We recently reported (7) on the long-term efficacy of oral beta-blocker and disopyramide therapy in patients with unexplained syncope and a positive head-up tilt test response. However, not all patients respond to initial therapy and it may actually worsen the presenting symptoms in some ( Fig. 8 ). Because of the potential for serious injury and incapacitating symptoms, it is imperative that an effective therapeutic strategy be identified at the initial test. Beta-blocker therapy and neurocardiogenic mechanisms of syncope. Using esmolol challenge, we identified two distinct groups with a favorable or unfavorable response to oral beta-blocker therapy at the initial tilt test in our study. It is unclear how beta-blockers prevent hypotension and bradycardia in patients with neurocardiogenic syncope. Several animal experiments (8) (9) (10) (11) (12) (13) have suggested that propranolol can decrease the discharge frequency of mechanoreceptors that are thought to initiate hypotension and bradycardia in susceptible persons. The investigators reported that this effect of propranolol was maintained even with isoproteronol and during increased left ventricular end-diastolic pressure when maximal mechanoreceptor activity was demonstrated. We recently demonstrated (14) a significant increase in epinephrine concentrations with little or no change in norepinephrine levels at the time of tilt-induced hypotension in patients with neurocardiogenic syncope. Echocardiographic data from our laboratory (15) have also suggested that a marked increase in left ventricular fractional shortening along with a decrease in left ventricular systolic volume always preceded the onset of hypotension in these patients. From these observations, it is thus conceivable that betablockers by their negative inotropic effect may at least partially inhibit the mechanoreceptor activity that is triggered by ventricular deformity and stretch. Sixteen patients had a negative head-up tilt test response during esmolol infusion and 11 patients continued to show a positive response to upright tilt during the infusion. The underlying reason for these interpatient differences is un- . At 5 min, the patient has 11 s of asystole. After resumption ofthe supine position and stabilization of heart rate and blood pressure, the patient is rechallenged with esmolol and the head-up tilt test is repeated (panel 11). Cardiac asystole again ensues at 3.5 min (F). After 5 days of oral metoprolol therapy, the tilt test is repeated as before (panel Ill). As depicted, the patient becomes syncopal and cardiac asystole again ensues 6 min after the start of the head-up tilt test.
clear. All patients with a positive head-up tilt test response with isoproterenol had a negative response during esmolol infusion. However, no other significant differences were demonstrated between the two groups. Significant bradycardia and asystole in some patients and hypotension preceding bradycardia in the majority of the patients during the baseline positive tilt test response were seen in both groups of patients ( Fig. 7 and 8 ). Baseline supine heart rate and mean maximal changes in heart rate from the supine to the upright position at baseline tilt and with esmolol were similar between the two groups.
Because the esmolol dose was titrated according to body weight, variations in dose could not have accounted for the differences in response. Furthermore, all patients who required isoproterenol for provocation of hypotension and syncope after a negative baseline head-up tilt test response had a negative response with esmolol and oral metoprolol. These observations suggest that hypersensitivity of the mechanoreceptors rather than the increased adrenergic tone may determine which patients will respond favorably to beta-blockers. Head-up tilt response to esmolol and metoprolol. Esmolol quite accurately predicted the outcome of oral metoprolol therapy in our patients. In contrast, intravenous metoprolol at the initial tilt test has been ineffective in predicting the response to oral beta-blockers in patients with neurocardiogenic syncope (16) . This discordant response of patients receiving intravenous metoprolol or esmolol may be due to several factors. Metoprolol is a lipid-soluble beta-blocker with a large volume of distribution (that is, 4.2 ± 0. 7 liters/kg) (17, 18) . After intravenous administration, its initial distribution may be favored to tissues with a high blood flow and lipid content. This may cause a delay in the development of an adequate degree of beta-receptor blockade in some tissues. A sevenfold interpatient variation in plasma levels of metoprolol has been reported (19) . These characteristics of metoprolol could account for the variable reported results. In contrast, esmolol, when infused with a loading dose, provides stable plasma concentrations within 4 min, with rapid dose-dependent beta-receptor blockade. High concentrations of esmolol (4 p.g/ml) have been seen when it is given at a loading dose of 500 p.glkg per min for 4 min followed by a 300 p.glkg per min maintenance infusion. This concentration can be maintained throughout the infusion. Its effects also dissipate rapidly, as demonstrated by increased levels of its metabolite ASL-8123, in a dose-dependent fashion (19, 20) . These properties make esmolol a more dependable and safe beta-blocker during the head-up tilt test.
It is difficult to estimate the exact oral dose of metoprolol that will be effective in an individual patient. There is no persistent interpatient correlation between the dosage of metoprolol and the therapeutic response (21) , and titration of the metoprolol dose, which might be useful in patients with hypertension or angina, may not be practical in patients with neurocardiogenic syncope. However, 50 mg twice daily seems to be an adequate dose in patients with neurocardiogenic dysfunction because results with this dose of oral metoprolol correlated favorably with results with esmolol, which was given at a very high dose.
Conclusions. In the electrophysiologic laboratory, esmolol can accurately predict the head-up tilt response to oral metoprolol. This information can be useful in formulating an appropriate therapeutic strategy at the initial head-up tilt test in patients with neurocardiogenic syncope. Patients with a negative head-up tilt test response can be safely treated with metoprolol. However, in patients who continue to demonstrate a positive response with esmolol challenge, alternative JACC Vol. 19, No. 2 February 1992:402-8 treatment strategies could be considered. Otherwise, these patients should be closely monitored while taking oral metoprolol because the long-term clinical efficacy of betablockers under these circumstances is not clear.
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